Table 4.
Adjusted odds ratio of AET discontinuation among women with breast cancer, by race/ethnicity, socioeconomic status, and geographic areas
| Characteristics | Immediate discontinuation | Discontinuation within 3 months | Discontinuation within 3–6 months | Discontinuation within 6–9 months | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|||||||||
| AOR | 95% CI | P | AOR | 95% CI | P | AOR | 95% CI | P | AOR | 95% CI | P | |
| Age (years) | ||||||||||||
| 20–34 | 2.49 | (1.14,5.45) | 0.02 | 3.26 | (1.62,6.58) | 0.00 | 3.41 | (1.35,8.61) | 0.01 | 1.26 | (0.36,4.46) | 0.72 |
| 35–49 | 1.5 | (1.00,2.25) | 0.05 | 1.52 | (1.04,2.22) | 0.03 | 1.11 | (0.67,1.82) | 0.68 | 0.88 | (0.51,1.49) | 0.63 |
| 50–64 | 1 | Reference | 1 | Reference | 1 | Reference | 1 | Reference | ||||
| Race/ethnicity | ||||||||||||
| White | 1 | 1 | 1 | 1 | ||||||||
| Black | 1.16 | (0.71,1.90) | 0.55 | 1.2 | (0.75,1.92) | 0.44 | 1.74 | (0.97,3.13) | 0.06 | 0.85 | (0.42,1.74) | 0.66 |
| Hispanic | 0.81 | (0.49,1.34) | 0.40 | 0.88 | (0.55,1.40) | 0.58 | 0.52 | (0.27,0.99) | 0.05 | 1.21 | (0.68,2.15) | 0.52 |
| Other | 0.71 | (0.27,1.88) | 0.49 | 0.78 | (0.31,1.92) | 0.58 | 1.16 | (0.42,3.19) | 0.77 | 0.23 | (0.03,1.77) | 0.16 |
| Tumor stage | ||||||||||||
| Local | 1 | 1 | 1 | 1 | ||||||||
| Regional | 1.33 | (0.89,2.00) | 0.17 | 1.46 | (1.00,2.14) | 0.05 | 0.91 | (0.56,1.49) | 0.72 | 0.72 | (0.43,1.22) | 0.22 |
| Poverty | ||||||||||||
| ≤ 16 | 1 | 1 | 1 | 1 | ||||||||
| 16.1–18.3 | 1.22 | (0.72,2.06) | 0.47 | 1 | (0.61,1.64) | 0.99 | 1.35 | (0.69,2.64) | 0.38 | 0.78 | (0.42,1.45) | 0.43 |
| ≥ 18.4 | 1 | (0.45,2.25) | 1.00 | 1.05 | (0.50,2.19) | 0.90 | 1.1 | (0.41,2.99) | 0.85 | 0.35 | (0.13,0.94) | 0.04 |
| Median income | ||||||||||||
| ≤ 33,502 | 1 | 1 | 1 | 1 | ||||||||
| 33,503–41,946 | 0.74 | (0.35,1.58) | 0.44 | 1.01 | (0.49,2.08) | 0.99 | 0.89 | (0.36,2.23) | 0.81 | 0.51 | (0.20,1.31) | 0.16 |
| ≥ 41,947 | 1.21 | (0.50,2.92) | 0.67 | 1.27 | (0.55,2.96) | 0.58 | 1.24 | (0.42,3.65) | 0.70 | 0.29 | (0.10,0.88) | 0.03 |
| DPC physicians per 100K population | ||||||||||||
| ≤ 103.9 | 1 | 1 | 1 | 1 | ||||||||
| 104–198.7 | 1.27 | (0.72,2.22) | 0.41 | 1.11 | (0.65,1.90) | 0.70 | 2.03 | (1.00,4.14) | 0.05 | 0.78 | (0.35,1.73) | 0.54 |
| ≥ 198.8 | 0.85 | (0.46,1.56) | 0.60 | 0.91 | (0.52,1.61) | 0.75 | 1.37 | (0.60,3.10) | 0.46 | 1.33 | (0.62,2.81) | 0.46 |
| TX–Mexico border | ||||||||||||
| No | 1 | 1 | 1 | 1 | ||||||||
| Yes | 0.30 | (0.10,0.87) | 0.03 | 0.46 | (0.18,1.20) | 0.11 | 1.27 | (0.41,3.98) | 0.68 | 0.59 | (0.17,2.08) | 0.41 |
| Region | ||||||||||||
| Metro | 1 | 1 | 1 | 1 | ||||||||
| Non-metro | 0.99 | (0.49,2.01) | 0.99 | 0.94 | (0.48,1.80) | 0.84 | 1.68 | (0.74,3.79) | 0.21 | 0.63 | (0.25,1.57) | 0.32 |
| Year of diagnosis | ||||||||||||
| 2000–2004 | 1 | 1 | 1 | 1 | ||||||||
| 2005–2007 | 0.75 | (0.48,1.18) | 0.21 | 0.76 | (0.50,1.15) | 0.19 | 1.1 | (0.65,1.83) | 0.73 | 1.21 | (0.69,2.13) | 0.50 |
| Chemotherapy | ||||||||||||
| No | 1 | 1 | 1 | 1 | ||||||||
| Yes | 0.99 | (0.64,1.52) | 0.95 | 0.98 | (0.65,1.46) | 0.91 | 1.16 | (0.69,1.96) | 0.57 | 1.19 | (0.69,2.05) | 0.53 |
| Radiation therapy | ||||||||||||
| No | 1 | 1 | 1 | 1 | ||||||||
| Yes | 0.64 | (0.43,0.95) | 0.03 | 0.63 | (0.44,0.92) | 0.02 | 0.87 | (0.55,1.39) | 0.57 | 0.85 | (0.51,1.39) | 0.51 |
| Surgery | ||||||||||||
| No | 1 | 1 | 1 | 1 | ||||||||
| Yes | 1.08 | (0.49,2.38) | 0.85 | 0.76 | (0.38,1.49) | 0.42 | 1.05 | (0.40,2.80) | 0.92 | 0.58 | (0.23,1.44) | 0.24 |
| Comorbidity scores | ||||||||||||
| 0 | 1 | 1 | 1 | 1 | ||||||||
| 1–2 | 1.03 | (0.65,1.65) | 0.89 | 1.01 | (0.65,1.57) | 0.97 | 1.12 | (0.64,1.94) | 0.69 | 1.19 | (0.66,2.15) | 0.57 |
| ≥ 3 | 1.53 | (0.89,2.61) | 0.12 | 1.48 | (0.90,2.46) | 0.12 | 1.19 | (0.59,2.40) | 0.64 | 1.28 | (0.63,2.58) | 0.49 |
*
The sample sizes vary across different discontinuous time group. For each group, n = 127, 149, 86, 76, respectively